Cytogenetics and genomics: an update

Bases for immunotherapy

Clonality

Drug combinations: the role of signaling pathways

Bone disease

Quality of life considerations in myeloma

Advances in Waldenstrom macroglobulinemia

Role of consolidation including double autologous transplant

Criteria for disease assessment

Novel imaging techniques

How to define smoldering myeloma?

Allogeneic stem cell transplantation for high-risk cytogenetics frontline

The case for monoclonal antibodies

The case for 2nd generation proteasome inhibitors

Practical considerations for the management of frail patients

Debate - Alkylating agents as part of frontline therapy in the elderly

Plasma cell leukemia

Ultra-high risk cytogenetics

Practical considerations when using anti-CD38 antibodies

Latest results of immunotherapy

Prevention of Progression in Multiple Myeloma

The road to cure in a transplant-eligible patient

Optimal management of myeloma in countries w/ limited resources

Role for salvage autologous transplantation

IMiDs and proteasome inhibitors

Monoclonal antibodies & Is there an optimal sequencing of therapy?

New drugs in the pipeline

Chemotherapy-based stem cell mobilization

Extramedullary disease

Debate - Continuous therapy as a standard of care

Debate - Autologous transplant frontline for the elderly

Debate - MRD-driven therapy

Debate - Should we treat smoldering myeloma?

Debate - Should we treat smoldering myeloma?

Do affordable & effective strategies in young patients exist?

Myeloma in 2025

MRD evaluation: Practical aspects